click below
click below
Normal Size Small Size show me how
IOS 11 Exam 2
Influenza/ avian flu
| Question | Answer |
|---|---|
| Influenza is an avian virus from family | Orthomyxovirisae |
| Antigenic shift | A totally new HA and sometimes a new NA as well |
| Antigenic drift | Minor changes driven by selective antibody pressure |
| Rates of mortality due to influenza | 5th leading cause of death in those >65 often coinfected with pneumonia |
| Spead of virus is | via respiratory droplets and travels into the pharynx or lower respitory epithelial |
| Replication of the influenza virus occurs in | nasal and tracheobronchial epithelial injury |
| Symptoms of influenza | Sudden onset, nonproductive cough,prominent HA, fatique, chest pain |
| Vaccine components | One strain Type B and two strains Type A |
| Subtype A contains | specific hemagglutin and neuraminidase surface proteins. |
| Adverse effects of influenza vaccine | injection site soreness, febrile reaction, hypersensitivity, Guillain Barre syndrome |
| Target for the influenza vaccine are | Age>65, Adults and children with metabolic diseases (DM, immunocomp) residents of LTC, COPD> 6 months, Children/teens of long term ASA, pregnancy |
| Prophylaxis of intranasal influenza vaccine | Cold adapted attenuated virus when placed on intranasal mucosa-bosy produced antibody |
| IM Trivalent vaccine contains | Type A (2) and Type B (1), two types of preparations Subvirion and purified surface -antigen two weeks for patient to produce antibodies |
| Treatment of Flu w/in 2 days of symptoms | Amantadiene & Rimantadine (M2 inhibitors) Zanamivir and Oseltamiflu (neuraminidase inhibtors) |
| Amantadine MOA | interferes with replication of influenza A through inhibition of viral M2 protein. Renal excretion |
| Amantadine indications | Children & adults prophylaxis and treatment |
| Timantadine MOA | interferes with replication of influenza A through inhibition of viral M2 protein. Hepatic excretion Less SE |
| Rimantadine indication | Adults-Treat & prophylaxis, Children Prophylaxis |
| Zanamivir MOA | Inhaled Drug - Virus neuraminidase cannot be cleaved thus they are not activated. Inhibti both Type A and Type B do not interfere with humoral response. |
| Zanamivir indication | Excellent for pregnancy, >7 Treatment, >5 prophylaxis |
| Oseltamivir MOA | Inhibits neuraminidase which cleaves the viron and activates it. It hibits Type A and Type B and does not intefere with the humoral response |
| Oseltamivir indication | Treatment & prophylaxis > 1year old, ok for COPD patients |
| Avian influenza strain | H5 N1 first detected in 1996 Guangdong, China |
| Most Avian influenza cases infected | Children and young adults |
| High relationship between Migration and | Spread of the H5 N1 |
| Clinical features of avian influenza | Incubation 2-8 days, N?V?D, nose bleeding, lower respiratory tract manidestations develop, multiorgan dysfunction often develops |
| Avian flu treated w/in 2 days with | Neuraminidase inhibitors, M2 inhibitors resistant |
| Prevention of avian flu | Avoid poultry in endemic areas, , do not swin in fowl water, avoid butchering |
| Pandamic requires 3 things | New influenza subtype, New subtype infects humans and causes serious disease, new subtype spreads easily and sustainably among humans |
| H5N1 is ______ transmissible | Not highly transmissible |